Xiaodong Wang Sells 40,468 Shares of BeiGene, Ltd. (NASDAQ:BGNE) Stock

BeiGene, Ltd. (NASDAQ:BGNE) insider Xiaodong Wang sold 40,468 shares of BeiGene stock in a transaction on Tuesday, November 26th. The stock was sold at an average price of $190.10, for a total transaction of $7,692,966.80. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

BeiGene Stock Up 4.3 %

Shares of BeiGene stock opened at $215.00 on Friday. The company has a debt-to-equity ratio of 0.05, a current ratio of 1.93 and a quick ratio of 1.72. BeiGene, Ltd. has a 1-year low of $126.97 and a 1-year high of $248.16. The business’s fifty day moving average price is $212.42 and its two-hundred day moving average price is $184.63. The company has a market capitalization of $20.94 billion, a P/E ratio of -26.09 and a beta of 0.63.

BeiGene (NASDAQ:BGNE) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($1.15) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.11) by ($0.04). The company had revenue of $1 billion for the quarter, compared to the consensus estimate of $983.26 million. BeiGene had a negative net margin of 25.94% and a negative return on equity of 25.12%. BeiGene’s revenue for the quarter was up 28.2% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $2.01 earnings per share. As a group, research analysts forecast that BeiGene, Ltd. will post -5.38 EPS for the current year.

Wall Street Analyst Weigh In

Several research analysts have recently commented on BGNE shares. Citigroup lifted their price target on shares of BeiGene from $269.00 to $288.00 and gave the company a “buy” rating in a report on Thursday, August 8th. TD Cowen upped their target price on BeiGene from $254.00 to $260.00 and gave the company a “buy” rating in a report on Wednesday, November 13th. JMP Securities started coverage on BeiGene in a report on Wednesday, September 18th. They issued a “market outperform” rating and a $288.00 price target on the stock. JPMorgan Chase & Co. boosted their price objective on BeiGene from $200.00 to $235.00 and gave the company an “overweight” rating in a research report on Tuesday, October 22nd. Finally, StockNews.com lowered BeiGene from a “buy” rating to a “hold” rating in a research report on Thursday, November 21st. Three investment analysts have rated the stock with a hold rating and five have given a buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $247.07.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Swedbank AB bought a new position in BeiGene during the 1st quarter valued at $2,596,000. Raymond James & Associates grew its holdings in BeiGene by 0.4% during the second quarter. Raymond James & Associates now owns 21,275 shares of the company’s stock worth $3,035,000 after acquiring an additional 76 shares during the period. EFG Asset Management North America Corp. raised its position in BeiGene by 21.7% in the second quarter. EFG Asset Management North America Corp. now owns 17,780 shares of the company’s stock worth $2,540,000 after acquiring an additional 3,170 shares in the last quarter. Van ECK Associates Corp lifted its holdings in BeiGene by 8.9% in the 2nd quarter. Van ECK Associates Corp now owns 95,577 shares of the company’s stock valued at $13,636,000 after acquiring an additional 7,816 shares during the last quarter. Finally, Fiera Capital Corp boosted its position in shares of BeiGene by 45.9% during the 2nd quarter. Fiera Capital Corp now owns 3,736 shares of the company’s stock valued at $533,000 after purchasing an additional 1,176 shares in the last quarter. 48.55% of the stock is currently owned by institutional investors.

BeiGene Company Profile

BeiGene, Ltd., through its subsidiaries, engages in the development and commercialization of oncology medicines worldwide. Its products include BRUKINSA to treat various blood cancers; TEVIMBRA to treat various solid tumor and blood cancers; PARTRUVIX for the treatment of various solid tumor malignancies; XGEVA to treat bone metastases from solid tumors and multiple myeloma, as well as giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; POBEVCY to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC); BAITUOWEI, to treat breast and prostate cancers; TAFINLAR and MEKINIST to treat NSCLC and melanoma; VOTRIENT for advance renal cell carcinoma; AFINITOR for advance renal cell carcinoma, NET, SEGA, & breast cancers; and ZYKADIA to treat ALK + NSCLC.